Omega-3 fatty acids (ω-3 PUFAs) are essential polyunsaturated fatty acids—primarily EPA (eicosapentaenoic acid, 20:5n-3) and DHA (docosahexaenoic acid, 22:6n-3)—that humans cannot synthesize in meaningful quantities. They serve as both structural membrane components and metabolic precursors for Specialized pro-resolving mediators (SPMs), actively terminating inflammation and enabling resolution. These molecules modulate membrane fluidity, lipid raft formation, transcriptional regulation, and cellular signaling through multiple parallel pathways.
Imagine a fire station with two critical functions. First, it prevents fires from starting: omega-3s in your cell membranes act like fire-resistant materials integrated into the building structure itself—they change membrane architecture so inflammatory signals (like NF-κB) have trouble gaining traction, like trying to light wet wood. But their second role is even more important: when a fire does break out, these omega-3s become the raw material for your specialized fire extinguishers—the SPMs (Resolvins, Maresins, Protectins). Without enough omega-3s stored in your membranes, your firefighting crew runs out of extinguisher fluid. The factory keeps churning out alarm bells (pro-inflammatory cytokines) but has no way to shut them off. The modern Western diet is like a city that banned fire extinguisher production 50 years ago—every small kitchen fire becomes a neighborhood-wide disaster because there's no resolution machinery left. Meanwhile, high omega-6:omega-3 ratios flood the market with combustible materials that compete for the same enzyme machinery, turning every spark into a blaze.
Omega-3 fatty acids exert anti-inflammatory and pro-resolving effects through five parallel molecular pathways:
1. Membrane Incorporation and Physical Effects
- EPA and DHA integrate into phospholipid bilayers (replacing arachidonic acid from omega-6 sources)
- Alter membrane fluidity and lipid raft composition → disrupts TLR4-MD2 complex assembly → reduces LPS-triggered TLR4 signaling
- Reduce availability of arachidonic acid for pro-inflammatory eicosanoid synthesis via COX-2 and 5-LOX
2. SPM Biosynthesis Cascade
graph TD
A[EPA in membrane] --> B[Phospholipase A2 release]
C[DHA in membrane] --> B
B --> D[15-LOX]
B --> E[5-LOX]
B --> F[12-LOX]
D --> G[E-series Resolvins from EPA]
E --> H[D-series Resolvins from DHA]
F --> I[Maresins from DHA]
D --> J[Protectins/Neuroprotectins from DHA]
G --> K[ALX-FPR2 receptor activation]
H --> K
I --> K
J --> K
K --> L["Resolution: efferocytosis, neutrophil apoptosis, anti-fibrotic"]
3. Transcriptional Regulation
- EPA and DHA act as endogenous ligands for PPARγ (peroxisome proliferator-activated receptor gamma)
- PPARγ activation → inhibits NF-κB nuclear translocation → reduces transcription of IL-6, TNF-α, IL-1β
- DHA also activates PPARα → upregulates fatty acid oxidation genes
4. HIF Inhibition and Metabolic Switching
- EPA directly inhibits HIF-1α stabilization under normoxic conditions
- Prevents Warburg-like glycolytic shift in activated immune cells
- Promotes oxidative metabolism in macrophages → M2 polarization
5. Inflammasome Modulation
- DHA metabolites inhibit NLRP3 inflammasome assembly
- Reduces cleavage of pro-IL-1β to active IL-1β
- Mechanism involves GPR120 receptor signaling → β-arrestin-2 recruitment → TAB1 sequestration
Cofactor Requirements for SPM Synthesis
- vitamin C: required for 15-LOX and 5-LOX enzyme activity
- Zinc: cofactor for delta-6-desaturase (rate-limiting in EPA→DHA conversion, though dietary intake bypasses this)
- Q10: electron donor in lipoxygenase reactions
- Molybdenum: cofactor for sulfite oxidase (indirect role in redox balance)
Omega-3 deficiency is a master switch failure in chronic inflammatory disease. The omega-6 to omega-3 ratio in modern diets averages 15-20:1 (versus ancestral 1-4:1), creating what Leo Pruimboom calls "resolution bankruptcy"—the immune system can initiate inflammation but cannot terminate it.
cPNI Priority Conditions:
Intervention Strategy:
- Therapeutic dosing: 2-4g combined EPA+DHA daily (not total fish oil)
- Form matters: Triglyceride or phospholipid forms absorb better than ethyl ester
- Timing: With meals containing fat for optimal absorption
- Biomarker: Target omega-3 index (EPA+DHA in RBC membranes) >8% (current Western average: 4-5%)
- Cofactors: Always combine with antioxidants (vitamin E, Curcumin) to prevent lipid peroxidation; add vitamin C and zinc for SPM synthesis
- Gene considerations: FADS1/FADS2 SNPs impair delta-6-desaturase (conversion of ALA→EPA), making direct EPA/DHA intake essential for these individuals
Evolutionary Mismatch:
The Cambrian Revolution coincided with aquatic DHA availability driving encephalization. Loss of vitamin C synthesis and reliance on dietary omega-3s reflect our evolutionary aquatic/coastal niche. Modern industrial seed oil consumption (omega-6 dominance) represents a 150-year deviation from 3 million years of human evolution.
- EPA (20:5n-3): Precursor for E-series Resolvins (RvE1, RvE2, RvE3) and substrate for competition with arachidonic acid at COX-2
- DHA (22:6n-3): Precursor for D-series Resolvins, Maresins, and Protectins; comprises 30% of brain gray matter lipid content and 50% of retinal photoreceptor membranes
- Therapeutic anti-inflammatory dose: 2-4g EPA+DHA daily (studies showing clinical benefit use ≥1.8g; cardiovascular protection requires ≥2.5g)
- Omega-3 index target: >8% (RBC membrane EPA+DHA) for optimal cardiovascular and inflammatory regulation
- Western omega-6:omega-3 ratio: 15-20:1 (ancestral human ratio: 1-4:1)
- Half-life in cell membranes: 6-8 weeks for full incorporation/turnover, requiring sustained supplementation for structural effects
- SPM production capacity: Reduced by 50-70% in aging, obesity, and chronic inflammatory states due to reduced 15-LOX expression
- Direct HIF inhibition: EPA prevents HIF-1α stabilization → blocks glycolytic shift in M1 macrophages
- COMT and depression: Patients with Met/Met COMT genotype may respond preferentially to EPA-dominant formulas (>60% EPA) rather than DHA
- Brain DHA turnover: 3-4 mg/day DHA lost from adult brain requiring constant dietary replacement; hippocampus has highest DHA turnover rate due to intense neurogenesis
- Clinical onset: Anti-inflammatory biomarker changes visible at 4-6 weeks; clinical symptom improvement typically 8-12 weeks
- Specialized pro-resolving mediators (SPMs) — omega-3s are obligate precursors for all SPM classes; without adequate EPA/DHA, resolution pathways fail
- Resolvins — E-series derived from EPA, D-series from DHA; bind ALX-FPR2 receptor to activate resolution programming
- Maresins — DHA-derived via 12-LOX pathway; promote M2 macrophage polarization and tissue repair
- Protectins — DHA-derived via 15-LOX; neuroprotective forms (NPD1) critical for retinal and hippocampal health
- omega-6 to omega-3 ratio — high ratio (>10:1) floods enzymatic pathways with arachidonic acid, outcompeting EPA/DHA and blocking SPM synthesis
- arachidonic acid — omega-6 PUFA competing for same enzymes (COX-2, 5-LOX, 15-LOX); high intake shifts balance toward pro-inflammatory eicosanoids
- 15-LOX — rate-limiting enzyme for resolvin and protectin synthesis; downregulated in obesity and aging
- ALX-FPR2 receptor — G-protein coupled receptor for RvD1, RvE1, and lipoxin A4; activates efferocytosis and neutrophil apoptosis
- NF-κB — omega-3s inhibit nuclear translocation via PPARγ activation and membrane-level interference with TLR4 signaling
- HIF — EPA directly inhibits HIF-1α, preventing metabolic switch to glycolysis in immune cells
- PPARγ — nuclear receptor activated by EPA/DHA; upregulates anti-inflammatory genes and inhibits NF-κB
- chronic inflammation — omega-3 deficiency removes "brakes" on inflammation; inadequate SPM synthesis prevents resolution
- resolution — omega-3-derived SPMs are THE molecular switches terminating inflammation and initiating tissue repair
- Depression — low DHA impairs hippocampal neurogenesis, BDNF expression, and synaptic plasticity; EPA reduces microglial activation
- BDNF — DHA increases BDNF transcription via CREB activation; critical for neuroplasticity and mood regulation
- neurogenesis — DHA required for neuronal progenitor proliferation in dentate gyrus; deficiency halts adult hippocampal neurogenesis
- Leaky mouth — oral barrier inflammation requires SPM-mediated resolution; omega-3 deficiency perpetuates periodontal disease
- Intestinal permeability — gut barrier repair depends on RvD1 and MaR1 to resolve mucosal inflammation and restore tight junction integrity
- Migraine — SPM deficiency allows sustained neuroinflammation; trigeminal nociceptor sensitization perpetuated by lack of resolution mediators
- Efferocytosis — RvD1 and MaR1 enhance macrophage clearance of apoptotic cells via upregulation of engulfment receptors
- M1 macrophages — omega-3s inhibit M1 polarization via HIF inhibition and promote M2 phenotype via PPARγ
- NLRP3 inflammasome — DHA metabolites inhibit NLRP3 assembly, reducing IL-1β maturation
- IL-6 — omega-3 supplementation reduces circulating IL-6 by 20-30% via NF-κB inhibition
- COMT — Met/Met genotype (slow catecholamine clearance) may require EPA-dominant omega-3 formulas for antidepressant effects
- vitamin C — essential cofactor for 15-LOX and 5-LOX; vitamin C deficiency blocks SPM synthesis even with adequate omega-3 intake
- Zinc — cofactor for delta-6-desaturase (ALA→EPA conversion) and antioxidant systems protecting PUFAs from peroxidation
- Module 7 (Evolutionary Medicine Part 2: Nutrition and Metabolism)
- Module 10 (Organs I: Gut, Liver, Oral Barrier)
- Module 13 (Connective Tissue and Movement)